



Sunil Arani Reddy

Clinical Associate Professor, Medicine - Oncology

CLINICAL OFFICE (PRIMARY)

- **Stanford Cancer Center**

875 Blake Wilbur Dr Rm CC2232

MC 6501

Stanford, CA 94305

Tel (650) 736-1234 Fax (650) 736-1373

Bio

CLINICAL FOCUS

- Cancer > Cutaneous (Dermatologic) Oncology
- lymphoma/melanoma/cutaneouslymphoma
- Medical Oncology

ACADEMIC APPOINTMENTS

- Clinical Associate Professor, Medicine - Oncology
- Member, Stanford Cancer Institute

PROFESSIONAL EDUCATION

- Medical Education: University of California at Irvine School of Medicine (1994) CA
- Board Certification: Medical Oncology, American Board of Internal Medicine (2015)
- Fellowship: Stanford University Hematology and Oncology Fellowship (2000) CA
- Residency: University of Michigan Health System Internal Medicine Residency (1997) MI
- Internship: University of Michigan Health System Internal Medicine Residency (1995) MI

LINKS

- Get a Second Opinion: <https://stanfordhealthcare.org/second-opinion/overview.html>

Research & Scholarship

CLINICAL TRIALS

- A Phase II/III Trial of Nivolumab, Ipilimumab, and GM-CSF in Patients With Advanced Melanoma, Recruiting
- Serial Ultrasound of Solid Tumor Lesions to Detect Early Response to Cancer Immunotherapy, Recruiting
- Using Nivolumab Alone or With Cabozantinib to Prevent Mucosal Melanoma Return After Surgery, Recruiting

- A Multi-Center Study of Ibrutinib in Combination With MEDI4736 in Subjects With Relapsed or Refractory Lymphomas, Not Recruiting
- A Pharmacokinetic/Pharmacodynamic Study of RO5185426 in Previously Treated Patients With Metastatic Melanoma, Not Recruiting
- A Randomized Phase II Study of Oral Sapacitabine in Patients With Advanced Cutaneous T-cell Lymphoma, Not Recruiting
- A Study for Participants With Relapsed Cutaneous T-Cell Lymphoma, Not Recruiting
- A Study of Atezolizumab (an Engineered Anti-Programmed Death-Ligand 1 [PDL1] Antibody) to Evaluate Safety, Tolerability and Pharmacokinetics in Participants With Locally Advanced or Metastatic Solid Tumors, Not Recruiting
- A Study of Atezolizumab Plus Cobimetinib and Vemurafenib Versus Placebo Plus Cobimetinib and Vemurafenib in Previously Untreated BRAFv600 Mutation-Positive Patients With Metastatic or Unresectable Locally Advanced Melanoma, Not Recruiting
- A Study of Bevacizumab With Carboplatin and Paclitaxel Chemotherapy for the First-Line Treatment of Patients With Metastatic Melanoma, Not Recruiting
- A Study of CDX-1127 (Varilumab) in Patients With Select Solid Tumor Types or Hematologic Cancers, Not Recruiting
- A Study of Cobimetinib Plus Atezolizumab Versus Pembrolizumab in Participants With Previously Untreated Advanced BRAFv600 Wild-Type Melanoma, Not Recruiting
- A Study of FORE8394 as a Single Agent in Patients With Advanced Unresectable Solid Tumors, Not Recruiting
- A Study of INCMGA00012 in Metastatic Merkel Cell Carcinoma (POD1UM-201), Not Recruiting
- A Study of NKTR-214 Combined With Nivolumab vs Nivolumab Alone in Participants With Previously Untreated Inoperable or Metastatic Melanoma, Not Recruiting
- A Study of Pharmacokinetic Drug Interaction Study of the Hedgehog Pathway Inhibitor GDC-0449 in Combination With Rosiglitazone or Combined Oral Contraceptive in Patients With Locally Advanced or Metastatic Solid Tumors That Are Refractory to Standard Therapy or for Whom No Standard Therapy Exists, Not Recruiting
- A Study of Subcutaneous Nivolumab + Relatlimab Fixed-dose Combination (FDC) in Previously Untreated Metastatic or Unresectable Melanoma, Not Recruiting
- A Study of the Anti-PD1 Antibody PDR001, in Combination With Dabrafenib and Trametinib in Advanced Melanoma, Not Recruiting
- A Study of Tilsotolimod in Combo With Ipilimumab vs Ipilimumab Alone in Subjects With Anti-PD-1 Refractory Melanoma, Not Recruiting
- A Study of Vemurafenib Adjuvant Therapy in Participants With Surgically Resected Cutaneous BRAF-Mutant Melanoma, Not Recruiting
- A Study to Assess Adjuvant Immunotherapy With Nivolumab Plus Relatlimab Versus Nivolumab Alone After Complete Resection of Stage III-IV Melanoma, Not Recruiting
- A Study to Compare the Administration of Pembrolizumab After Surgery Versus Administration Both Before and After Surgery for High-Risk Melanoma, Not Recruiting
- A Study to Test the Safety of the Investigational Drug Selitrectinib in Children and Adults That May Treat Cancer, Not Recruiting
- A Trial of Intratumoral Injections of SD-101 in Combination With Pembrolizumab in Patients With Metastatic Melanoma or Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma, Not Recruiting
- An Investigational Immuno-therapy Study to Determine the Safety of Urelumab Given in Combination With Nivolumab in Solid Tumors and B-cell Non-Hodgkin's Lymphoma, Not Recruiting
- An Open Label Study to Evaluate the Safety and Efficacy of Mechlorethamine(MCH) 0.04% Formulation in Mycosis Fungoides, Not Recruiting
- An Open-Label Expanded Access Study of the Melphalan/Hepatic Delivery System (HDS) in Patients With Hepatic Dominant Ocular Melanoma, Not Recruiting
- Brentuximab Vedotin (SGN-35) in Patients With Mycosis Fungoides With Variable CD30 Expression Level, Not Recruiting
- Capecitabine in Treating Patients With Advanced or Recurrent Squamous Cell Carcinoma of the Skin, Not Recruiting
- Carboplatin and Paclitaxel With or Without Sorafenib Tosylate in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery, Not Recruiting
- Compassionate Use Trial for Unresectable Melanoma With Ipilimumab, Not Recruiting
- Dasatinib in Treating Patients With Locally Advanced or Metastatic Mucosal Melanoma, Acral Melanoma, or Vulvovaginal Melanoma That Cannot Be Removed By Surgery, Not Recruiting
- Efficacy, Safety and Tolerability Study of SHAPE in IA, IB or IIA Cutaneous T-cell Lymphoma, Not Recruiting
- Everolimus (RAD001) in Primary Therapy of Waldenstrom's Macroglobulinemia, Not Recruiting
- Extension Study in Subjects Who Relapsed After Complete Response on Study KW-0761-001, Not Recruiting

- Forodesine in the Treatment of Cutaneous T-Cell Lymphoma, Not Recruiting
- High-Dose Interferon Alfa in Treating Patients With Stage II or Stage III Melanoma, Not Recruiting
- Intrahepatic Delivery of SD-101 by Pressure-Enabled Regional Immuno-oncology (PERIO), With Checkpoint Blockade in Adults With Metastatic Uveal Melanoma, Not Recruiting
- Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery, Not Recruiting
- Ipilimumab With or Without Sargramostim in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery, Not Recruiting
- ITIL-168 in Advanced Melanoma, Not Recruiting
- JTX-2011 Alone and in Combination With Anti-PD-1 or Anti-CTLA-4 in Subjects With Advanced and/or Refractory Solid Tumors, Not Recruiting
- Lenalidomide in Treating Patients With Relapsed Mycosis Fungoides/Sezary Syndrome, Not Recruiting
- Low-dose (12 Gy) TSEBT+Vorinostat Versus Low-dose TSEBT Monotherapy in Mycosis Fungoides, Not Recruiting
- Nivolumab and BO-112 Before Surgery for the Treatment of Resectable Soft Tissue Sarcoma, Not Recruiting
- Pembrolizumab in Treating Patients With Advanced Merkel Cell Cancer, Not Recruiting
- Percutaneous Hepatic Perfusion in Patients With Hepatic-dominant Ocular Melanoma, Not Recruiting
- Ph II of Non-myeloablative Allogeneic Transplantation Using TLI & ATG In Patients w/ Cutaneous T Cell Lymphoma, Not Recruiting
- Physician/Patient Choice of Either High-Dose Recombinant Interferon Alfa-2B or Ipilimumab, Versus Pembrolizumab in Treating Patients With Stage III-IV High Risk Melanoma That Has Been Removed by Surgery, Not Recruiting
- Pilot Ipilimumab in Stage IV Melanoma Receiving Palliative Radiation Therapy, Not Recruiting
- Pilot Study of the Safety/Efficacy of Combination Checkpoint Blockade + External Beam Radiotherapy in Stage IV Melanoma, Not Recruiting
- Pralatrexate and Bexarotene in Patients With Relapsed or Refractory Cutaneous T-cell Lymphoma, Not Recruiting
- Safety and Efficacy of IMCgp100 Versus Investigator Choice in Advanced Uveal Melanoma, Not Recruiting
- Safety and Efficacy of Nitrogen Mustard in Treatment of Mycosis Fungoides, Not Recruiting
- Safety Study of MGD009 in B7-H3-expressing Tumors, Not Recruiting
- Safety Study to Evaluate Monoclonal Antibody KW-0761 in Subjects With Peripheral T-cell Lymphoma, Not Recruiting
- Safety, Pharmacodynamics (PD), Pharmacokinetics (PK) Study of SHP141 in 1A, 1B, or 2A Cutaneous T-Cell Lymphoma (CTCL), Not Recruiting
- Safety, Tolerability and Pharmacokinetics of MRG-106 in Patients With Mycosis Fungoides (MF), CLL, DLBCL or ATLL, Not Recruiting
- Study Comparing the Efficacy of MEK162 Versus Dacarbazine in Unresectable or Metastatic NRAS Mutation-positive Melanoma, Not Recruiting
- Study of KW-0761 Versus Vorinostat in Relapsed/Refractory CTCL, Not Recruiting
- Study of Oral LBH589 in Adult Participants With Refractory/Resistant Cutaneous T-Cell Lymphoma (CTCL), Not Recruiting
- Study of Pembrolizumab (MK-3475) in Adults With Recurrent/Metastatic Cutaneous Squamous Cell Carcinoma (cSCC) or Locally Advanced Unresectable cSCC (MK-3475-629/KEYNOTE-629), Not Recruiting
- Study of Pralatrexate in Patients With Relapsed or Refractory Cutaneous T-cell Lymphoma, Not Recruiting
- Study of the Safety, Pharmacokinetics and Efficacy of Tinostamustine in Patients With Advanced Solid Tumors., Not Recruiting
- Testing Pembrolizumab Versus Observation in Patients With Merkel Cell Carcinoma After Surgery, STAMP Trial, Not Recruiting

Publications

PUBLICATIONS

- **Toward the Development of Functional Biomarker Assays: Analysis of Neoadjuvant Intralesional Oncolytic Virus Response in High-Risk Stage II Melanoma**
Kirane, A., Lee, D., Ahmad, M., Sharma, S., Serasanambati, M., Lowe, M., Applebee, C., Safrygina, E., Swetter, S., Reddy, S., Warner, A., Funchain, P., Wang, et al
SPRINGER.2024: S33-S34

- **ESC Cardio-Oncology Guidelines: A Triumph-But Are We Overscreening?** *JACC. CardioOncology*
Witteles, R. M., Reddy, S. A.
2023; 5 (1): 133-136
- **Intracranial Control With Combination BRAF and MEK Inhibitor Therapy in Patients With Metastatic Melanoma.** *Cureus*
Hui, C., Wu, Y. F., Liu, K., Sandhu, N., Blomain, E., Binkley, M. S., Gephart, M. H., Chang, S. D., Li, G. H., Reddy, S. A., Soltys, S. G., Pollom, E.
2022; 14 (11): e31838
- **Health Care Utilization and Costs in Systemic Therapies for Metastatic Melanoma from 2016 to 2020.** *The oncologist*
Qian, M. F., Betancourt, N. J., Pineda, A., Maloney, N. J., Nguyen, K. A., Reddy, S. A., Hall, E. T., Swetter, S. M., Zaba, L. C.
2022
- **Identification of Pathogenic Immune Cell Subsets Associated With Checkpoint Inhibitor-Induced Myocarditis.** *Circulation*
Zhu, H., Galdos, F. X., Lee, D., Waliyany, S., Vivian Huang, Y., Ryan, J., Dang, K., Neal, J. W., Wakelee, H. A., Reddy, S. A., Srinivas, S., Lin, L. L., Witteles, et al
2022: 101161CIRCULATIONAHA121056730
- **FOCUS phase 3 trial results: Percutaneous hepatic perfusion (PHP) with melphalan for patients with ocular melanoma liver metastases (PHP-OCM-301/301A).**
Zager, J. S., Orloff, M. M., Ferrucci, P., Glazer, E., Ejaz, A., Richtig, E., Ochsenreither, S., Lowe, M. C., Reddy, S. A., Beasley, G., Gesierich, A., Dummer, R., Arance, et al
LIPPINCOTT WILLIAMS & WILKINS.2022
- **Management of Immunotherapy-Related Toxicities, Version 1.2022, NCCN Clinical Practice Guidelines in Oncology.** *Journal of the National Comprehensive Cancer Network : JNCCN*
Thompson, J. A., Schneider, B. J., Brahmer, J., Achufusi, A., Armand, P., Berkenstock, M. K., Bhatia, S., Budde, L. E., Chokshi, S., Davies, M., Elshoury, A., Gesthalter, Y., Hegde, et al
2022; 20 (4): 387-405
- **The complexity of carcinosarcoma.** *Oncology (Williston Park, N.Y.)*
Reddy, S.
1800; 35 (12): 814
- **Intracranial Response to Combination BRAF and MEK Inhibitor Therapy in Patients with Metastatic Melanoma**
Hui, C., Wu, Y., Liu, K., Sandhu, N., Blomain, E., Binkley, M., Gephart, M., Chang, S., Li, G., Reddy, S., Gibbs, I., Soltys, S., Pollom, et al
LIPPINCOTT WILLIAMS & WILKINS.2021: S48-S49
- **Use of a computer model and care coaches to increase advance care planning conversations for patients with metastatic cancer**
Gupta, D., Fardeen, T., Teuteberg, W., Seevaratnam, B., Asuncion, M., Alves, N., Rogers, B., Neal, J. W., Fan, A. C., Parikh, D., Patel, M. I., Shah, S., Srinivas, et al
LIPPINCOTT WILLIAMS & WILKINS.2021
- **Complete remission from intralesional talimogene laherparepvec for regionally advanced Merkel cell carcinoma in an immunocompromised solid organ transplant patient.** *JAAD case reports*
Hirotsu, K. E., Hua, V., Tran, A. T., Morris, L., Reddy, S. A., Kwong, B. Y., Zaba, L. C.
2021; 13: 144-146
- **Percutaneous hepatic perfusion (PHP) with melphalan for patients with ocular melanoma liver metastases: Preliminary results of FOCUS (PHP-OCM-301/301A) phase III trial.**
Zager, J. S., Orloff, M., Ferrucci, P., Glazer, E., Ejaz, A., Richtig, E., Ochsenreither, S., Lowe, M. C., Reddy, S. A., Beasley, G., Gesierich, A., Dummer, R., Arance, et al
LIPPINCOTT WILLIAMS & WILKINS.2021
- **Three-year survival, correlates and salvage therapies in patients receiving first-line pembrolizumab for advanced Merkel cell carcinoma.** *Journal for immunotherapy of cancer*
Nghiem, P., Bhatia, S., Lipson, E. J., Sharfman, W. H., Kudchadkar, R. R., Brohl, A. S., Friedlander, P. A., Daud, A., Kluger, H. M., Reddy, S. A., Boulmay, B. C., Riker, A., Burgess, et al
2021; 9 (4)
- **Myocarditis Surveillance with High-Sensitivity Troponin I During Cancer Treatment with Immune Checkpoint Inhibitors.** *JACC. CardioOncology*

- Waliany, S., Neal, J. W., Reddy, S., Wakelee, H., Shah, S. A., Srinivas, S., Padda, S. K., Fan, A. C., Colevas, A. D., Wu, S. M., Witteles, R. M., Zhu, H.
2021; 3 (1): 137–39
- **Liquid biopsy proteomics of uveal melanoma reveals biomarkers associated with metastatic risk.** *Molecular cancer*
Velez, G., Nguyen, H. V., Chemudupati, T., Ludwig, C. A., Toral, M., Reddy, S., Mruthyunjaya, P., Mahajan, V. B.
2021; 20 (1): 39
 - **Prognostic value of bone marrow metabolism on pretreatment 18F-FDG PET/CT in patients with metastatic melanoma treated with anti-PD-1 therapy.** *Journal of nuclear medicine : official publication, Society of Nuclear Medicine*
Nakamoto, R., Zaba, L. C., Liang, T., Reddy, S. A., Davidzon, G., Aparici, C. M., Nguyen, J., Moradi, F., Iagaru, A., Franc, B. L.
2021
 - **Immune Profiling and Causal Antigen Discovery in Mouse and Human Models of Immune Checkpoint Inhibitor-induced Myocarditis**
Zhu, H., Lee, D., Sarah, W., Galdos, F. X., D'Addabbo, J., Fowler, M. B., Reddy, S., Heather, W., Neal, J. W., Witteles, R., Maecker, H. T., Davis, M., Nguyen, et al
LIPPINCOTT WILLIAMS & WILKINS.2020
 - **Imaging characteristics and diagnostic performance of F-18-FDG PET/CT for melanoma patients who demonstrate hyperprogressive disease when treated with immunotherapy**
Nakamoto, R., Zaba, L., Rosenberg, J., Reddy, S., Nobashi, T., Davidzon, G., Aparici, C., Nguyen, J., Moradi, F., Iagaru, A., Franc, B.
SOC NUCLEAR MEDICINE INC.2020
 - **Prognostic value of volumetric PET parameters at early response evaluation in melanoma patients treated with immunotherapy**
Nakamoto, R., Zaba, L., Rosenberg, J., Reddy, S., Nobashi, T., Davidzon, G., Aparici, C., Nguyen, J., Moradi, F., Iagaru, A., Franc, B.
SOC NUCLEAR MEDICINE INC.2020
 - **A Prospective, Phase 1 Trial of Nivolumab, Ipilimumab, and Radiotherapy in Patients with Advanced Melanoma.** *Clinical cancer research : an official journal of the American Association for Cancer Research*
Postow, M. A., Knox, S. J., Goldman, D. A., Elhanati, Y., Mavinkurve, V., Wong, P., Halpenny, D. F., Reddy, S. A., Vado, K. P., McCabe, D., Ramirez, K. A., Macri, M., Schwarzenberger, et al
2020
 - **Durability of response in metastatic melanoma patients after combined treatment with radiation therapy and ipilimumab.** *Melanoma management*
Sodji, Q. H., Gutkin, P. M., Swetter, S. M., Reddy, S. A., Hiniker, S. M., Knox, S. J.
2020; 7 (1): MMT36
 - **Economics of alternative dosing strategies for pembrolizumab and nivolumab at a single academic cancer center.** *Cancer medicine*
Hall, E., Zhang, J., Kim, E. J., Hwang, G., Chu, G., Bhatia, S., Reddy, S.
2020
 - **Autologous tumor cell vaccine induces antitumor T cell immune responses in patients with mantle cell lymphoma: A phase I/II trial.** *The Journal of experimental medicine*
Frank, M. J., Khodadoust, M. S., Czerwinski, D. K., Haabeth, O. A., Chu, M. P., Miklos, D. B., Advani, R. H., Alizadeh, A. A., Gupta, N. K., Maeda, L. S., Reddy, S. A., Laport, G. G., Meyer, et al
2020; 217 (9)
 - **Intracranial Tumor Control Following Immune-Related Adverse Events and Discontinuation of Immunotherapy for Melanoma.** *World neurosurgery*
Zhang, M. n., Rodrigues, A. J., Bhambhani, H. P., Fatemi, P. n., Pollom, E. L., Gibbs, I. C., Thomas, R. P., Soltys, S. G., Hancock, S. L., Chang, S. D., Reddy, S. A., Gephart, M. H., Li, et al
2020
 - **NCCN Guidelines Insights: Management of Immunotherapy-Related Toxicities, Version 1.2020.** *Journal of the National Comprehensive Cancer Network : JNCCN*
Thompson, J. A., Schneider, B. J., Brahmer, J., Andrews, S., Armand, P., Bhatia, S., Budde, L. E., Costa, L., Davies, M., Dunnington, D., Ernstoff, M. S., Frigault, M., Kaffenberger, et al
2020; 18 (3): 230–41
 - **"Giant cell arteritis manifesting as retinal arterial occlusion and paracentral acute middle maculopathy in a patient on pembrolizumab for metastatic uveal melanoma".** *American journal of ophthalmology case reports*

- Narala, R. n., Reddy, S. A., Mruthyunjaya, P. n.
2020; 20: 100891
- **Prognostic value of volumetric PET parameters at early response evaluation in melanoma patients treated with immunotherapy.** *European journal of nuclear medicine and molecular imaging*
Nakamoto, R. n., Zaba, L. C., Rosenberg, J. n., Reddy, S. A., Nobashi, T. W., Davidzon, G. n., Aparici, C. M., Nguyen, J. n., Moradi, F. n., Igaru, A. n., Franc, B. L.
2020
 - **A phase 1b, open-label, investigator-initiated, proof-of-concept study of pembrolizumab for advanced basal cell carcinomas**
Chang, A., Duy Tran, Cannon, J., Li, S., Jeng, M., Rieger, K., Reddy, S., Sarin, K., Colevas, D.
MOSBY-ELSEVIER.2019: AB8
 - **Economic analysis of alternative pembrolizumab and nivolumab dosing strategies at an academic cancer center.**
Hall, E., Zhang, J., Kim, E., Hwang, G., Bhatia, S., Reddy, S. A.
AMER SOC CLINICAL ONCOLOGY.2019
 - **Phase 1b/2, open label, multicenter, study of the combination of SD-101 and pembrolizumab in patients with advanced/metastatic melanoma resistant to anti-PD-1/PD-L1 therapy.**
Amin, A., Milhem, M. M., Long, G. V., Hoimes, C. J., Medina, T., Conry, R., Lao, C. D., Daniels, G. A., Reddy, S. A., Andtbacka, R., Barve, M. A., Shaheen, M. F., Tueting, et al
AMER SOC CLINICAL ONCOLOGY.2019
 - **Management of Immunotherapy-Related Toxicities. Version 1.2019** *JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK*
Thompson, J. A., Schneider, B. J., Brahmer, J., Andrews, S., Armand, P., Bhatia, S., Budde, L. E., Costa, L., Davies, M., Dunnington, D., Ernstoff, M. S., Frigault, M., Hoffner, et al
2019; 17 (3): 255–88
 - **Durable Tumor Regression and Overall Survival in Patients With Advanced Merkel Cell Carcinoma Receiving Pembrolizumab as First-Line Therapy.** *Journal of clinical oncology : official journal of the American Society of Clinical Oncology*
Nghiem, P., Bhatia, S., Lipson, E. J., Sharfman, W. H., Kudchadkar, R. R., Brohl, A. S., Friedlander, P. A., Daud, A., Kluger, H. M., Reddy, S. A., Boulmay, B. C., Riker, A. I., Burgess, et al
2019: JCO1801896
 - **Predicting Response to Immunotherapy by Evaluating Tumors, Lymphoid Cell-Rich Organs, and Immune-Related Adverse Events Using FDG-PET/CT.** *Clinical nuclear medicine*
Nobashi, T., Baratto, L., Reddy, S. A., Srinivas, S., Toriihara, A., Hatami, N., Yohannan, T. K., Mitra, E.
2019
 - **Complete Response of Metastatic Melanoma to Local Radiation and Immunotherapy: 6.5 Year Follow-Up.** *Cureus*
Gutkin, P. M., Hiniker, S. M., Swetter, S. M., Reddy, S. A., Knox, S. J.
2018; 10 (12): e3723
 - **Pembrolizumab for advanced basal cell carcinoma: an investigator-initiated, proof-of-concept study.** *Journal of the American Academy of Dermatology*
Chang, A. L., Tran, D. C., Cannon, J. G., Li, S. n., Jeng, M. n., Patel, R. n., Van der Bokke, L. n., Pague, A. n., Brotherton, R. n., Rieger, K. E., Satpathy, A. T., Yost, K. E., Reddy, et al
2018
 - **Phase I Trial: SABR and Ipilimumab-Letter.** *Clinical cancer research : an official journal of the American Association for Cancer Research*
Hiniker, S. M., Reddy, S. A., Swetter, S. M., Knox, S. J.
2017; 23 (1): 320
 - **A Prospective Clinical Trial Combining Radiation Therapy With Systemic Immunotherapy in Metastatic Melanoma.** *International journal of radiation oncology, biology, physics*
Hiniker, S. M., Reddy, S. A., Maecker, H. T., Subrahmanyam, P. B., Rosenberg-Hasson, Y., Swetter, S. M., Saha, S., Shura, L., Knox, S. J.
2016; 96 (3): 578-588
 - **Romidepsin for the treatment of relapsed/refractory cutaneous T-cell lymphoma (mycosis fungoides/Sézary syndrome): Use in a community setting.** *Critical reviews in oncology/hematology*
Reddy, S. A.

2016; 106: 99-107

- **PD-1 Blockade with Pembrolizumab in Advanced Merkel-Cell Carcinoma** *NEW ENGLAND JOURNAL OF MEDICINE*
Nghiem, P. T., Bhatia, S., Lipson, E. J., Kudchadkar, R. R., Miller, N. J., Annamalai, L., Berry, S., Chartash, E. K., Daud, A., Fling, S. P., Friedlander, P. A., Kluger, H. M., Kohrt, et al
2016; 374 (26): 2542-2552
- **Tumor DNA in cerebral spinal fluid reflects clinical course in a patient with melanoma leptomeningeal brain metastases** *JOURNAL OF NEURO-ONCOLOGY*
Li, Y., Pan, W., Connolly, I. D., Reddy, S., Nagpal, S., Quake, S., Gephart, M. H.
2016; 128 (1): 93-100
- **Toward rapid learning in cancer treatment selection: An analytical engine for practice-based clinical data.** *Journal of biomedical informatics*
Finlayson, S. G., Levy, M., Reddy, S., Rubin, D. L.
2016; 60: 104-113
- **Phase II Investigator-Initiated Study of Brentuximab Vedotin in Mycosis Fungoides and Sézary Syndrome With Variable CD30 Expression Level: A Multi-Institution Collaborative Project.** *Journal of clinical oncology*
Kim, Y. H., Tavallaee, M., Sundram, U., Salva, K. A., Wood, G. S., Li, S., Rozati, S., Nagpal, S., Krathen, M., Reddy, S., Hoppe, R. T., Nguyen-Lin, A., Weng, et al
2015; 33 (32): 3750-3758
- **Phase II Investigator-Initiated Study of Brentuximab Vedotin in Mycosis Fungoides and Sézary Syndrome With Variable CD30 Expression Level: A Multi-Institution Collaborative Project.** *Journal of clinical oncology*
Kim, Y. H., Tavallaee, M., Sundram, U., Salva, K. A., Wood, G. S., Li, S., Rozati, S., Nagpal, S., Krathen, M., Reddy, S., Hoppe, R. T., Nguyen-Lin, A., Weng, et al
2015; 33 (32): 3750-3758
- **Clinically significant responses achieved with romidepsin across disease compartments in patients with cutaneous T-cell lymphoma** *LEUKEMIA & LYMPHOMA*
Kim, E. J., Kim, Y. H., Rook, A. H., Lerner, A., Duvic, M., Reddy, S., Robak, T., Becker, J. C., Samtsov, A., McCulloch, W., Waksman, J., Whittaker, S.
2015; 56 (10): 2847-2854
- **Involution of eruptive melanocytic nevi on combination BRAF and MEK inhibitor therapy.** *JAMA dermatology*
Chen, F. W., Tseng, D., Reddy, S., Daud, A. I., Swetter, S. M.
2014; 150 (11): 1209-1212
- **Involution of Eruptive Melanocytic Nevi on Combination BRAF and MEK Inhibitor Therapy** *JAMA DERMATOLOGY*
Chen, F. W., Tseng, D., Reddy, S., Daud, A. I., Swetter, S. M.
2014; 150 (11): 1209-1212
- **Markedly improved overall survival in 10 consecutive patients with metastatic basal cell carcinoma** *BRITISH JOURNAL OF DERMATOLOGY*
Danial, C., Lingala, B., Balise, R., Oro, A. E., Reddy, S., Colevas, A., Chang, A. L.
2013; 169 (3): 673-676
- **Markedly improved overall survival in 10 consecutive patients with metastatic basal cell carcinoma.** *British journal of dermatology*
Danial, C., Lingala, B., Balise, R., Oro, A. E., Reddy, S., Colevas, A., Chang, A. L.
2013; 169 (3): 673-676
- **A Systemic Complete Response of Metastatic Melanoma to Local Radiation and Immunotherapy** *TRANSLATIONAL ONCOLOGY*
Hiniker, S. M., Chen, D. S., Reddy, S., Chang, D. T., Jones, J. C., Mollick, J. A., Swetter, S. M., Knox, S. J.
2012; 5 (6): 404-407
- **Final Results From a Multicenter, International, Pivotal Study of Romidepsin in Refractory Cutaneous T-Cell Lymphoma** *JOURNAL OF CLINICAL ONCOLOGY*
Whittaker, S. J., Demierre, M., Kim, E. J., Rook, A. H., Lerner, A., Duvic, M., Scarisbrick, J., Reddy, S., Robak, T., Becker, J. C., Samtsov, A., McCulloch, W., Kim, et al
2010; 28 (29): 4485-4491
- **A Phase II Study of SGN-30 in Cutaneous Anaplastic Large Cell Lymphoma and Related Lymphoproliferative Disorders** *CLINICAL CANCER RESEARCH*
Duvic, M., Reddy, S. A., Pinter-Brown, L., Korman, N. J., Zic, J., Kennedy, D. A., Lorenz, J., Sievers, E. L., Kim, Y. H.

2009; 15 (19): 6217-6224

- **Prognostic Factors in Primary Cutaneous Anaplastic Large Cell Lymphoma Characterization of Clinical Subset With Worse Outcome** *49th Annual Meeting of the American-Society-of-Hematology*
Woo, D. K., Jones, C. R., Vanoli-Storz, M. N., Kohler, S., Reddy, S., Advani, R., Hoppe, R. T., Kim, Y. H.
AMER MEDICAL ASSOC.2009: 667-74
- **Indolent primary cutaneous B-cell lymphoma: Experience using systemic rituximab** *JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY*
Morales, A. V., Advani, R., Horwitz, S. M., Riaz, N., Reddy, S., Hoppe, R. T., Kim, Y. H.
2008; 59 (6): 953-957
- **Plant-produced idiotype vaccines for the treatment of non-Hodgkin's lymphoma: Safety and immunogenicity in a phase I clinical study** *PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA*
McCormick, A. A., Reddy, S., Reinl, S. J., Cameron, T. I., Czerwinski, D. K., Vojdani, F., Hanley, K. M., Garger, S. J., White, E. L., Novak, J., Barrett, J., Holtz, R. B., Tuse, et al
2008; 105 (29): 10131-10136
- **Molecular rescue of tumour-specific T cell receptor idiotype from T cell lymphomas** *BRITISH JOURNAL OF HAEMATOLOGY*
Reddy, S. A., Levy, R.
2004; 124 (5): 626-628
- **CD30(+) cutaneous lymphoproliferative disorders: The Stanford experience in lymphomatoid papulosis and primary cutaneous anaplastic large cell lymphoma** *JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY*
Liu, H. L., Hoppe, R. T., Kohler, S., Harvell, J. D., Reddy, S., Kim, Y. H.
2003; 49 (6): 1049-1058
- **T cell antigen receptor vaccines for active therapy of T cell malignancies** *Conference on Basic and Clinical Relevant Biology of Cutaneous T Cell Lymphoma*
Reddy, S. A., Okada, C., Wong, C., Bahler, D., Levy, R.
NEW YORK ACAD SCIENCES.2001: 97-105
- **Favorable treatment outcome in non-Hodgkin's lymphoma patients with "poor" mobilization of peripheral blood progenitor cells** *BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION*
Stockerl-Goldstein, K. E., Reddy, S. A., Horning, S. J., Blume, K. G., Chao, N. J., Hu, W. W., JOHNSTON, L. J., Long, G. D., Strober, S., Wong, R. M., Feiner, R. H., Kohler, S., Negrin, et al
2000; 6 (5): 506-512